by Scott Larrivee | Oct 14, 2025 | News
Agreement includes Actinium-225 (Ac-225) and Lutetium-177 (Lu-177) to support Ariceum’s therapeutic programs WEST VALLEY CITY, Utah and BERLIN, Germany – Oct. 14, 2025 – Nusano, a physics company transforming the production of radioisotopes, and Ariceum Therapeutics...
by Scott Larrivee | Jun 17, 2025 | News
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies’...
by Scott Larrivee | Dec 9, 2024 | News
VALENCIA, Calif. and SYDNEY, Australia – Dec. 9, 2024 – Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid...
by Scott Larrivee | Oct 1, 2024 | News
Funding supports development and commercialization of broad array of isotopes for medical, commercial and industrial uses VALENCIA, Calif. – Oct. 1, 2024 – Nusano, Inc., a physics company transforming the production of radioisotopes, today announced a Series C...
by Scott Larrivee | Jul 10, 2024 | News
VALENCIA, Calif. and BOCA RATON, Fla. – July 10, 2024 – Nusano Inc. (Nusano), a physics company transforming the production of medical radioisotopes, and PharmaLogic Holdings Corp. (PharmaLogic), a leading radiopharmaceutical contract development and manufacturing...
